Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2007

View Archived Issues

Long-acting antithrombotic oligosaccharides profiled at sanofi-aventis

New therapeutic options for cancer imparted in recent patents

Clinical protocol submitted in India for phase II trial of bavituximab in NSCLC

Recent Bristol-Myers Squibb patent discloses novel therapeutics for thrombotic disorders

Topical ketoprofen patch fails to meet primary endpoint in phase III trials

R-763 begins new phase I study for advanced malignancies

TRC-093 begins phase I study in cancer

In vitro efficacy of CD-160130, a PDE4 inhibitor, in chronic lymphocytic leukemia

Preclinical and clinical data on Novo Nordisk's recombinant FVIIa analogue NN-1731

New uses for the PDE5 inhibitor udenafil

FM-19 shows activity in murine models of thrombosis

Affiris mimotope-based Alzheimer's disease vaccine enters the clinic

Topline findings from North American Zuidex study

Novel diagnostic agents disclosed in recent Bracco patent

Amgen and Daiichi collaborate on development of denosumab in Japan

Sciele Pharma and Addrenex agree to market Clonicel in North America

LAB reports positive interim results from phase II study of LAB GHRH

LifeCycle Pharma to begin phase II trial of LCP-AtorFen for high cholesterol

TZP-101 receives fast track designation for treatment of gastroparesis

Update on GTx's two pivotal phase III trials of Acapodene

Avalon begins enrollment for phase II trial of AVN-944

Positive phase II results for dose-finding study of oral Rambazole

Lubiprostone filed for IBS-C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...